La terapia con i nuovi DAA in pazienti affetti da coinfezione HIV/HCV: esperienza di un centro
Diletta Barbanotti(IRCCS Humanitas Research Hospital), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Stefania Salpietro(IRCCS Ospedale San Raffaele), Liviana Della Torre(Vita-Salute San Raffaele University), Emanuela Messina(Vita-Salute San Raffaele University), Vinci Concetta(IRCCS Ospedale San Raffaele), Sabrina Bagaglio(Vita-Salute San Raffaele University), D Zandonà(IRCCS Ospedale San Raffaele), Giulia Morsica(Vita-Salute San Raffaele University), Hamid Hasson(Vita-Salute San Raffaele University), Rossana Melzi(IRCCS Ospedale San Raffaele)
Cited by 0
Related Papers
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
|The Lancet|1992|393
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Human Papillomavirus Infection and Associated Cervical Disease in Human Immunodeficiency Virus–Infected Women: Effect of Highly Active Antiretroviral Therapy
|The Journal of Infectious Diseases|2001|173
Discontinuation of Secondary Prophylaxis against<i>Pneumocystis carinii</i>Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy
|New England Journal of Medicine|2001|168